Wave Chasing Huntington’s Accelerated Approval Based On Caudate Atrophy Surrogate

 
• By Alaric DeArment

The biotech plans a pivotal trial that would support accelerated approval of the Takeda-partnered antisense oligonucleotide, WVE-003, and will discuss it with regulators before the end of the year.

Wave believes a registrational trial with about 150 patients could last 12 to 18 months. • Source: Shutterstock

More from Clinical Trials

More from R&D